The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels. Other relevant AD-related investigational biomarkers may also be assessed in the provided samples. Apolipoprotein E (ApoE) genetic status will be evaluated with a serum sample.
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.